# Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients

> **NCT05236647** · PHASE3 · COMPLETED · sponsor: **University Hospital, Akershus** · enrollment: 60 (actual)

## Conditions studied

- Pain Cancer

## Interventions

- **DRUG:** Morphine

## Key facts

- **NCT ID:** NCT05236647
- **Lead sponsor:** University Hospital, Akershus
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-08
- **Primary completion:** 2025-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05236647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05236647, "Subcutaneous Versus Intravenous Morphine When Switching From Oral to Parenteral Route in Palliative Cancer Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05236647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*